NASDAQ · NTLA
Healthcare · Biotechnology
$11.36
Down-$0.51 (-4.30%)
Updated Sep 16, 2026, 10:06 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NTLA closed at $11.36 after 20 trading sessions, down 2.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $11.75 | $11.82 | $11.2427 | $11.36 | 3.99M |
| Sep 14, 2026 | $11.645 | $12.11 | $11.645 | $11.87 | 2.6M |
| Sep 11, 2026 | $12.10 | $12.19 | $11.69 | $11.74 | 2.71M |
| Sep 10, 2026 | $11.90 | $11.955 | $11.66 | $11.93 | 3.92M |
| Sep 9, 2026 | $12.50 | $12.82 | $12.19 | $12.21 | 4.93M |
| Sep 8, 2026 | $12.83 | $12.89 | $12.425 | $12.74 | 4.13M |
| Sep 4, 2026 | $12.59 | $12.96 | $12.52 | $12.74 | 2.8M |
| Sep 3, 2026 | $12.86 | $12.92 | $12.40 | $12.68 | 3M |
| Sep 2, 2026 | $12.67 | $13.13 | $12.28 | $12.76 | 3.25M |
| Sep 1, 2026 | $12.52 | $12.81 | $12.34 | $12.685 | 2.18M |
| Aug 31, 2026 | $12.64 | $12.85 | $12.44 | $12.73 | 2.93M |
| Aug 28, 2026 | $13.11 | $13.49 | $12.68 | $12.87 | 3.44M |
| Aug 27, 2026 | $13.26 | $13.45 | $13.00 | $13.11 | 2.45M |
| Aug 26, 2026 | $13.38 | $13.50 | $12.98 | $13.19 | 2.71M |
| Aug 25, 2026 | $12.84 | $13.73 | $12.76 | $13.51 | 4.09M |
| Aug 24, 2026 | $12.60 | $12.79 | $12.24 | $12.56 | 3.12M |
| Aug 21, 2026 | $12.65 | $13.13 | $12.65 | $12.84 | 3.35M |
| Aug 20, 2026 | $12.95 | $13.04 | $12.29 | $12.44 | 4.7M |
| Aug 19, 2026 | $12.10 | $13.35 | $12.01 | $13.28 | 6.11M |
| Aug 18, 2026 | $11.80 | $12.10 | $11.44 | $11.60 | 3.18M |
The latest Smart Investors Daily articles mentioning NTLA.
NTLA research
Company profile and research snapshot.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Citizens | Market Outperform | — |
| Sep 9, 2026 | Wedbush | Neutral | — |
| Sep 9, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 25, 2026 | Citizens | Market Outperform | — |
| Aug 7, 2026 | Evercore ISI Group | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 14, 2026
Intellia Therapeutics, Inc. (NTLA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDTCompany ParticipantsJohn Leonard -...
Yahoo · Sep 10, 2026
Intellia Therapeutics, Inc. (NASDAQ:NTLA) entered a five-year senior secured credit facility with OrbiMed for up to $400 million and drew $75 million at closing. The remaining $325 million depends on milestones or further lender agreement. The facility bears interest at an annual rate equal to the greater of 3% or the one-month Secured Overnight Financing […]
Yahoo · Sep 9, 2026
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
Benzinga · Sep 9, 2026
Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTLA.
